Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 15/20 | 0.43 |
| ▸ | HSD11B2 | P80365 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL233311 | 0.77 | HSD11B1 (0.44) | HSD11B1HSD11B2 | |
| SCHEMBL13223479 | 0.74 | GRIN2D (0.52) | EPHX2 | |
| SCHEMBL942696 | 0.74 | HSD11B1 (0.46) | HSD11B1HSD11B2EPHX2 | |
| SCHEMBL10046792 | 0.74 | HSD11B1 (0.46) | HSD11B1HSD11B2EPHX2 | |
| SCHEMBL16380619 | 0.74 | HSD11B1 (0.46) | HSD11B1HSD11B2EPHX2DPP4 | |
| SCHEMBL10046791 | 0.74 | HSD11B1 (0.46) | HSD11B1HSD11B2EPHX2 | |
| SCHEMBL27509398 | 0.74 | HSD11B1 (0.36) | HSD11B1HSD11B2EPHX2DPP4 | |
| SCHEMBL12968026 | 0.73 | HSD11B1 (0.40) | HSD11B1HSD11B2EPHX2DPP4 | |
| SCHEMBL10234486 | 0.73 | HSD11B1 (0.40) | HSD11B1HSD11B2EPHX2DPP4 | |
| SCHEMBL3041989 | 0.73 | HSD11B1 (0.54) | HSD11B1HSD11B2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2238126-B1 | DERIVATIVES OF TETRAHYDROQUINOXALINE UREA, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI SA (FR) | 2014-11-05 | — | — | EP | claimed |
| US-8211892-B2 | Tetrahydroquinoxaline urea derivatives | SANOFI-AVENTIS (FR) | 2012-07-03 | — | — | US | claimed |
| CN-110305123-A | A kind of compound containing adamantane and its purposes in treating cancer | 成都海创药业有限公司 | 2019-10-08 | — | — | CN | disclosed |
| US-8530657-B2 | Substituted adamantanes and their therapeutic application | SANOFI (FR) | 2013-09-10 | — | — | US | disclosed |
| US-20120245148-A1 | TETRAHYDROQUINOXALINE UERA DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| US-8211892-B2 | Tetrahydroquinoxaline urea derivatives | SANOFI-AVENTIS (FR) | 2012-07-03 | — | — | US | disclosed |
| US-8017638-B2 | Isoxazole derivative and isothiazole derivative having inhibitory activity on 11β-hydroxysteroid dehydrogenase type 1 | SHIONOGI & CO., LTD. (JP) | 2011-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245148-A1 | TETRAHYDROQUINOXALINE UERA DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | UGDH, HNMT, NNMT | HSD11B1 2913/4885HSD11B2 3024/4885EPHX2 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.